Phase II Study of Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Adenoid cystic carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 07 Jun 2022 16 of the planned 45 patients (ACC cohort 9 of 20 pts, non-ACC 7 of 25) have been accrued as per Study design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Study design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 23 Jul 2021 Status changed from not yet recruiting to recruiting.